- Record: found
- Abstract: found
- Article: not found
Evaluation of SRD5A2 sequence variants in susceptibility to hereditary and sporadic prostate cancer.
Bao-Li Chang
1 ,
S Lilly Zheng ,
Sarah D Isaacs ,
Aubrey R Turner ,
Eugene R Bleecker ,
Patrick C Walsh ,
Deborah A Meyers ,
William B Isaacs ,
Jianfeng Xu
Jun 15 2003
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
The 5 alpha-reductase type II (SRD5A2) catalyzes the conversion of testosterone into the more potent androgen, dihydrotestosterone (DHT), and is thus believed to be the key enzyme for the control of intracellular DHT level in the prostate. Several single nucleotide polymorphisms (SNPs) in the SRD5A2 gene have been found to alter enzymatic activities and were associated with prostate cancer risk or clinical features in several case-control studies. However, the role of SRD5A2 sequence variants in the susceptibility to hereditary prostate cancer (HPC) has not been evaluated to date.